Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.
2.

The influence of Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS on potentially carcinogenic bacterial activity in human colon.

Hatakka K, Holma R, El-Nezami H, Suomalainen T, Kuisma M, Saxelin M, Poussa T, Mykkänen H, Korpela R.

Int J Food Microbiol. 2008 Dec 10;128(2):406-10. doi: 10.1016/j.ijfoodmicro.2008.09.010. Epub 2008 Sep 27.

PMID:
18945506
3.

Persistence of probiotic strains in the gastrointestinal tract when administered as capsules, yoghurt, or cheese.

Saxelin M, Lassig A, Karjalainen H, Tynkkynen S, Surakka A, Vapaatalo H, Järvenpää S, Korpela R, Mutanen M, Hatakka K.

Int J Food Microbiol. 2010 Dec 15;144(2):293-300. doi: 10.1016/j.ijfoodmicro.2010.10.009. Epub 2010 Oct 21.

PMID:
21074284
4.
5.

Effects of multispecies probiotic combination on helicobacter pylori infection in vitro.

Myllyluoma E, Ahonen AM, Korpela R, Vapaatalo H, Kankuri E.

Clin Vaccine Immunol. 2008 Sep;15(9):1472-82. doi: 10.1128/CVI.00080-08. Epub 2008 Jun 25.

6.

A probiotic mixture including galactooligosaccharides decreases fecal β-glucosidase activity but does not affect serum enterolactone concentration in men during a two-week intervention.

Kekkonen RA, Holma R, Hatakka K, Suomalainen T, Poussa T, Adlercreutz H, Korpela R.

J Nutr. 2011 May;141(5):870-6. doi: 10.3945/jn.110.137703. Epub 2011 Mar 16.

PMID:
21411613
7.

A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention.

Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R.

Aliment Pharmacol Ther. 2005 Sep 1;22(5):387-94.

8.

Absence of adverse events in healthy individuals using probiotics--analysis of six randomised studies by one study group.

Tapiovaara L, Lehtoranta L, Poussa T, Mäkivuokko H, Korpela R, Pitkäranta A.

Benef Microbes. 2016;7(2):161-9. doi: 10.3920/BM2015.0096. Epub 2015 Dec 21.

PMID:
26689224
9.

Clinical studies on alleviating the symptoms of irritable bowel syndrome.

Kajander K, Korpela R.

Asia Pac J Clin Nutr. 2006;15(4):576-80.

10.

Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota.

Myllyluoma E, Ahlroos T, Veijola L, Rautelin H, Tynkkynen S, Korpela R.

Int J Antimicrob Agents. 2007 Jan;29(1):66-72. Epub 2006 Dec 1.

PMID:
17141481
11.

Effects of probiotic Lactobacillus rhamnosus GG and Propionibacterium freudenreichii ssp. shermanii JS supplementation on intestinal and systemic markers of inflammation in ApoE*3Leiden mice consuming a high-fat diet.

Oksaharju A, Kooistra T, Kleemann R, van Duyvenvoorde W, Miettinen M, Lappalainen J, Lindstedt KA, Kovanen PT, Korpela R, Kekkonen RA.

Br J Nutr. 2013 Jul 14;110(1):77-85. doi: 10.1017/S0007114512004801. Epub 2012 Dec 5.

PMID:
23211714
12.

Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study.

Myllyluoma E, Veijola L, Ahlroos T, Tynkkynen S, Kankuri E, Vapaatalo H, Rautelin H, Korpela R.

Aliment Pharmacol Ther. 2005 May 15;21(10):1263-72.

13.

Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome.

Kajander K, Krogius-Kurikka L, Rinttilä T, Karjalainen H, Palva A, Korpela R.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):463-73.

14.

Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells.

Oksaharju A, Kankainen M, Kekkonen RA, Lindstedt KA, Kovanen PT, Korpela R, Miettinen M.

World J Gastroenterol. 2011 Feb 14;17(6):750-9. doi: 10.3748/wjg.v17.i6.750.

15.

Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial.

Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, Tuure T, Kuitunen M.

Pediatrics. 2008 Jul;122(1):8-12. doi: 10.1542/peds.2007-1192.

PMID:
18595980
16.

Calcium phosphate supplementation increases faecal Lactobacillus spp. in a randomised trial of young adults.

Dahl WJ, Ford AL, Coppola JA, Lopez D, Combs W, Rohani A, Ukhanova M, Culpepper T, Tompkins TA, Christman M, Mai V.

Benef Microbes. 2016 Feb;7(1):3-10. doi: 10.3920/BM2014.0168. Epub 2015 Oct 27.

PMID:
26503737
17.

Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota.

Kajander K, Myllyluoma E, Rajilić-Stojanović M, Kyrönpalo S, Rasmussen M, Järvenpää S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R.

Aliment Pharmacol Ther. 2008 Jan 1;27(1):48-57. Epub 2007 Oct 5.

18.

Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes.

Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, Korpela R, Palva A.

BMC Gastroenterol. 2010 Sep 19;10:110. doi: 10.1186/1471-230X-10-110.

19.

Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.

Jones ML, Martoni CJ, Parent M, Prakash S.

Br J Nutr. 2012 May;107(10):1505-13. doi: 10.1017/S0007114511004703. Epub 2011 Nov 9.

PMID:
22067612
20.

Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults.

Kekkonen RA, Lummela N, Karjalainen H, Latvala S, Tynkkynen S, Jarvenpaa S, Kautiainen H, Julkunen I, Vapaatalo H, Korpela R.

World J Gastroenterol. 2008 Apr 7;14(13):2029-36.

Supplemental Content

Support Center